Men diagnosed with metastatic prostate cancer that lacks the PTEN protein now have a targeted drug option for the first time.

Smart PSA boosted targeted screening and found more aggressive prostate cancers in Black men in Chicago trials.

Patients with advanced prostate cancer may need periodic imaging scans to catch tumor growth even with stable levels of ...

For many men, a prostate cancer scare starts with one number. A PSA result comes back high, and ...

A large analysis suggests that a multivariable risk assessment tool, called Stockholm3, can detect substantially more ...

A 74-year-old man with an active lifestyle and no family history of prostate cancer presented with mild urinary hesitancy and ...

The expanded indication makes risankizumab the first IL-23 inhibitor available for pediatric patients weighing under 40kg with plaque psoriasis or psoriatic arthritis, supported by phase 3 OptIMMize ...

The interleukin 23 inhibitor was approved for treating moderate-to-severe plaque psoriasis in adults in 2019 and for active ...

Indications now include pediatric plaque psoriasis and active PsA starting at age 6, positioning risankizumab as the first US-approved IL-23(p19) inhibitor for <40 kg pediatric patients. Weight-tiered ...

Lupin Limited has received tentative approval from the FDA for its abbreviated new drug application (ANDA) for enzalutamide ...

View post: 2026 Donruss Elite Baseball: Everything to Know Before Hobby Boxes Hit Shelves July 3 Hey, collectors, here’s another thrilling story of the day. The card market just experienced a massive ...